Shopping Cart
- Remove All
- Your shopping cart is currently empty
(R)-SR-C-107 is an orally active inhibitor developed based on ENL (containing YEAST domain protein), designed to target acute myeloid leukemia (AML). The inhibitor has an IC50 of 40 nM and a KD of 144 nM for ENL. In a xenograft mouse model of AML, (R)-SR-C-107 demonstrated in vivo efficacy, achieving a tumor regression rate of 45% at a dosage of 200 mg/kg (PO; QD).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | (R)-SR-C-107 is an orally active inhibitor developed based on ENL (containing YEAST domain protein), designed to target acute myeloid leukemia (AML). The inhibitor has an IC50 of 40 nM and a KD of 144 nM for ENL. In a xenograft mouse model of AML, (R)-SR-C-107 demonstrated in vivo efficacy, achieving a tumor regression rate of 45% at a dosage of 200 mg/kg (PO; QD). |
Molecular Weight | 389.45 |
Formula | C21H23N7O |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.